90 related articles for article (PubMed ID: 24290212)
1. Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant.
Fava C; Rege-Cambrin G; Busca A; Gottardi E; Daraio F; Saglio G
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S272-5. PubMed ID: 24290212
[No Abstract] [Full Text] [Related]
2. Maintenance therapy with dasatinib after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Teng CL; Yu JT; Chen HC; Hwang WL
Ann Hematol; 2013 Aug; 92(8):1137-9. PubMed ID: 23307602
[No Abstract] [Full Text] [Related]
3. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F
Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Caocci G; Vacca A; Ledda A; Murgia F; Piras E; Greco M; Arras M; Atzeni S; Littera R; La Nasa G
Biol Blood Marrow Transplant; 2012 Apr; 18(4):652-4. PubMed ID: 22240733
[No Abstract] [Full Text] [Related]
5. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation.
Ishida Y; Terasako K; Oshima K; Sakamoto K; Ashizawa M; Sato M; Kikuchi M; Kimura S; Nakasone H; Okuda S; Kako S; Yamazaki R; Nishida J; Kanda Y
Int J Hematol; 2010 Oct; 92(3):542-6. PubMed ID: 20824399
[TBL] [Abstract][Full Text] [Related]
7. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Gruber F; Mustjoki S; Porkka K
Br J Haematol; 2009 Jun; 145(5):581-97. PubMed ID: 19388927
[TBL] [Abstract][Full Text] [Related]
8. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
[TBL] [Abstract][Full Text] [Related]
9. Impact of allogeneic haematopoietic stem cell transplantation in the outcome of Ph+ acute lymphoblastic leukaemia treated with an imatinib-containing regimen.
Costa LJ
Br J Haematol; 2009 Sep; 146(5):576-7. PubMed ID: 19555375
[No Abstract] [Full Text] [Related]
10. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
Burke MJ; Cao Q; Trotz B; Weigel B; Kumar A; Smith A; Verneris MR
Pediatr Blood Cancer; 2009 Dec; 53(7):1289-94. PubMed ID: 19731318
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
12. Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
Wernstedt P; Brune M; Andersson PO; Gustavsson B; Stockelberg D; Wadenvik H
Bone Marrow Transplant; 2002 Dec; 30(12):971-3. PubMed ID: 12476293
[TBL] [Abstract][Full Text] [Related]
13. Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation.
Ribera JM; García O; Montesinos P; Brunet S; Abella E; Barrios M; González-Campos J; Bravo P; Amigo ML; Hernández-Rivas JM
Br J Haematol; 2012 Oct; 159(1):78-81. PubMed ID: 22823211
[TBL] [Abstract][Full Text] [Related]
14. Favorable outcome of unrelated cord blood transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Onishi Y; Sasaki O; Ichikawa S; Inokura K; Katsuoka Y; Ohtsuka Ohba R; Okitsu Y; Kohata K; Ohguchi H; Fukuhara N; Yokoyama H; Yamada MF; Yamamoto J; Ishizawa K; Kameoka J; Harigae H
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1093-7. PubMed ID: 21277378
[TBL] [Abstract][Full Text] [Related]
15. TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation.
Kobayashi K; Miyagawa N; Mitsui K; Matsuoka M; Kojima Y; Takahashi H; Ootsubo K; Nagai J; Ueno H; Ishibashi T; Sultana S; Okada Y; Akimoto S; Okita H; Matsumoto K; Goto H; Kiyokawa N; Ohara A
Pediatr Blood Cancer; 2015 Jun; 62(6):1058-60. PubMed ID: 25400122
[TBL] [Abstract][Full Text] [Related]
16. Achievement of complete donor-type chimerism and remission with dasatinib in Philadelphia chromosome-positive ALL relapsing after allogeneic transplantation.
Conchon M; Sanabani SS; Bendit I; Serpa M; Filho UA; de Barros Ferreira P; Novaes MM; Saboya R; Llacer-Dorliac PE; Dulley FL
Bone Marrow Transplant; 2010 Jun; 45(6):1125-6. PubMed ID: 19855440
[No Abstract] [Full Text] [Related]
17. [Second-generation tyrosine kinase inhibitors combined with allogeneic hematopoietic stem cell transplant for Philadelphia chromosome positive leukemia].
Yu X; Li C; Wu X; Ye L; Liu H; Ma C; Ma J; Gu C; Wu D
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):129-33. PubMed ID: 24606654
[TBL] [Abstract][Full Text] [Related]
18. Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.
Sonmez M; Cobanoglu U; Ovali E; Omay SB
J Clin Pharm Ther; 2008 Jun; 33(3):329-30. PubMed ID: 18452422
[No Abstract] [Full Text] [Related]
19. Phase II study of intensive post-remission chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia and lymphoblastic lymphoma: Japan Clinical Oncology Group Study, JCOG9402.
Azuma T; Tobinai K; Takeyama K; Shibata T; Hidaka M; Kurosawa M; Kasai M; Chou T; Fukushima N; Mukai K; Tsukasaki K; Shimoyama M;
Jpn J Clin Oncol; 2012 May; 42(5):394-404. PubMed ID: 22422899
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.
Pfeifer H; Wassmann B; Bethge W; Dengler J; Bornhäuser M; Stadler M; Beelen D; Vucinic V; Burmeister T; Stelljes M; Faul C; Dreger P; Kiani A; Schäfer-Eckart K; Schwerdtfeger R; Lange E; Kubuschok B; Horst HA; Gramatzki M; Brück P; Serve H; Hoelzer D; Gökbuget N; Ottmann OG;
Leukemia; 2013 Jun; 27(6):1254-62. PubMed ID: 23212150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]